Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: We studied 19 diabetic subjects randomly assigned to either 45 mg pioglitazone (n = 8) or 10 mg (median dose) glipizide (n = 11) for 12 weeks. Body water content was measured with deuterated water, body composition by dual-energy X-ray absorptiometry and computed tomography, and cardiac output and systemic vascular resistance by acetylene rebreathing technique both before and after therapy. RESULTS:
Pioglitazone increased (P < 0.001 from baseline) total body water (+2.4 +/- 0.5 l) accounting for 75% of the total weight gain (+3.1 +/- 2.0 kg) but did not alter vascular endothelial growth factor concentrations. Total abdominal (-32.2 +/- 19 cm(2)) and visceral fat area (-16.1 +/- 8 cm(2)) tended to decrease with pioglitazone but increased (P < 0.02 for differences between groups) with glipizide (+38.4 +/- 17 cm(2) abdominal; +19.1 +/- 9 cm(2) visceral). Pioglitazone tended to reduce (P = 0.05) diastolic (-8.4 +/- 4 mmHg) and mean (-9.5 +/- 5 mmHg; P = 0.08) blood pressure and reduced (P < 0.001) systemic vascular resistance (2,785 +/- 336 vs. 2,227 +/- 136 dynes/s per m(2)), while there were no differences in these parameters with glipizide. Neither therapy altered circulating catecholamine concentrations. CONCLUSIONS:
|
Authors | Ananda Basu, Michael D Jensen, Frances McCann, Debabrata Mukhopadhyay, Michael J Joyner, Robert A Rizza |
Journal | Diabetes care
(Diabetes Care)
Vol. 29
Issue 3
Pg. 510-4
(Mar 2006)
ISSN: 0149-5992 [Print] United States |
PMID | 16505497
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Thiazolidinediones
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Pioglitazone
- Glipizide
|
Topics |
- Adult
- Aged
- Blood Glucose
(metabolism)
- Body Composition
- Body Fat Distribution
- Body Water
(metabolism)
- Diabetes Mellitus, Type 2
- Female
- Glipizide
(therapeutic use)
- Glycated Hemoglobin
(metabolism)
- Hemodynamics
(drug effects)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Male
- Middle Aged
- Pioglitazone
- Thiazolidinediones
(therapeutic use)
- Vascular Endothelial Growth Factor A
(blood)
|